Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy

Expert Opinion on Biological Therapy

Volumn 18, Issue , 2018, Pages 77-83

  Danielli, Riccardo ^a   Cisternino, Filomena ^a   Giannarelli, Diana ^b   Calabrò, Luana ^a   Camerini, Roberto ^c   Savelli, Vinno ^d   Bova, Giovanni ^a   Dragonetti, Rosella ^c   Di Giacomo, Anna Maria ^a   Altomonte, Maresa ^a   Maio, Michele ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c R D Dept   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

Author keywords

checkpoint blockade; CTLA 4; long term survival; Thymosin alpha 1

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; THYMOSIN ALPHA1; ANTINEOPLASTIC AGENT; CTLA4 PROTEIN, HUMAN; DACARBAZINE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CANCER SURVIVOR; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; IMMUNITY; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; SURVIVAL RATE; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; DRUG POTENTIATION; IMMUNOLOGY; MELANOMA; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN TUMOR; SURVIVAL ANALYSIS; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE CHECKPOINTS; CLINICAL TRIALS, PHASE II AS TOPIC; CTLA-4 ANTIGEN; DACARBAZINE; DRUG SYNERGISM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IPILIMUMAB; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS; SURVIVAL ANALYSIS; THYMALFASIN; TIME FACTORS; YOUNG ADULT;

EID: 85051060309     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1080/14712598.2018.1494717     Document Type: Article

References (25)

1. Sadozai H, Gruber T, Hunger RE, et al. Recent and future directions in immunotherapy of cutaneous melanoma. Front Immunol. 2017;8:1617
2. McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF (V600E) and BRAF (V600F) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomized, open-label study. Lancet Oncol. 2014 Mar;15(3):323–332
3. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open- label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358–365
4. Long GV, Stroyakovsky DL, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015 Aug 1;386(9992):444–451
5. Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Sep 23;363(13):1290
6. Ribas A, Hanson DC, Noe DA, et al. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist. 2007 Jul;12(7):873–883
7. Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4-treatment (checkmate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015 Apr;16(4):375–384
8. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015 Jun;372(26):2521–2532
9. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017 Oct 5;377(14):1345–1356
10. Hodi FS, Kluger H, Sznol M, et al. Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial. Cancer Res. 2016 Jul;76(14 Suppl):abstr CT001
11. Danielli R, Fonsatti E, Calabrò L, et al. Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond. Ann N Y Acad Sci. 2012;1270:8–12
12. Garaci E, Mastino A, Pica F, et al. Combination treatment using thymosin alpha one and interferon after cyclophosphamide is able to cure lewis lung carcinoma in mice. Cancer Immunol Immunother. 1990;32(3):154–160
13. Rasi G, Silecchia G, Sinibaldi-Vallebona P, et al. Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. Int J Cancer. 1994 Jun 1;57(5):701–705
14. Giuliani C, Napolitano G, Mastino A, et al. Thymosin alpha 1 regulates MHC expression in FRTL-5 cells at trascriptional level. Eur JImmunol. 2000 Mar;30(3):778–786
15. Sinibaldi Vallebona P, Pierimarchi P, Moroni G, et al. Thymalfasin up-regulates tumor antigen expression in colorectal cancer cells. Tumor Biol. 2002;23:45
16. Maio M, Mackiewicz A, Testori A, et al. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol. 2010 Apr;28(10):1780–1787
17. O’Day S, Weber J, Lebbe C, et al. Effect of Ipilimumab treatment on 18-months survival: update of patients (pts) with advanced melanoma treated with 10mg/Kg ipilimumab in three phase II clinical trials. J Clin Oncol. 2009;27(15 suppl):9033
18. Altomonte M, Di Giacomo A, Queirolo P, et al. Clinical experience with ipilimumab 10 mg/Kg in patients with melanoma treated at Italian centres as part of a european expanded access programme. J Exp Clin Cancer Res. 2013 Oct 25;32:82
19. Ascierto PA, Simeone E, Sileni VC, et al. Clinical experience with ipilimumab 3 mg/Kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med. 2014 May 7;12:116
20. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previiously untreated metastatic melanoma. N Engl J Med. 2011 June 30;364(26):2517–2526
21. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015 Jun 10;33(17):1889–1894
22. Di Giacomo AM, Calabrò L, Danielli R, et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/Kg within an expanded access programme. Cancer Immunol Immunother. 2013 Jun;62(6):1021–1028
23. Ferrucci PF, Gandini S, Battaglia A, et al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer. 2015 Jun;112(12):1904–1910
24. Ferrucci PF, Gandini S, Cocorocchio E, et al. Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma. Oncotarget. 2017 Aug 1;8(45):79809–79815
25. Ascierto PA, Del Vecchio M, Robert C, et al. Ipilimumab 10 mg/Kg versus ipilimumab 3mg/Kg in patients with unresectable or metastatic melanoma: a randomized, double blind, multicentre, phase 3 trial. Lancet Oncol. 2017 Apr;18(5):611–622